Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBody™-enabled GPCRs with DyNAbind’s Dynamic […]
Archive for the
‘Press Releases’ Category
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and […]
Confo Therapeutics raises €30 million in Series A financing Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The […]
Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine Ghent, Belgium, 28 February 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, […]
Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology Licence provides Confo Therapeutics with exclusive access to ‘Megabody’ Technology for High Resolution Cryo-Electron Microscopy evaluation of G-Protein Coupled Receptors, strengthening its drug discovery engine • Confo Therapeutics secures exclusive, worldwide license to new proprietary Megabody technology for GPCRs • […]
Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property Ghent, Belgium, 6 December 2018 – Confo Therapeutics, an emerging drug discovery company, today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019. Frank is joining the Company from Ablynx, now a wholly […]
Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities Ghent, Belgium – February 20, 2018 – Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for […]
Confo Therapeutics enters into drug discovery collaboration with Roche Ghent, Belgium – December 19, 2017 Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) […]
Confo Therapeutics enters into drug discovery collaboration with Lundbeck Ghent, Belgium – September 26, 2017 Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company specializing in psychiatric and neurological disorders. The goal of the collaboration is to deploy […]
Confo Therapeutics is awarded EUR 2.6M in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology Ghent, Belgium – February 1, 2017 Confo Therapeutics, an emerging drug discovery company, today announced that it has received a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). […]